GlassScriptPhysician profile
Sharla E Morgan
NPI 1003151853
$2,434.28
in general payments reported to CMS, 2019-2025
29 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $640 · 2023: $445 · 2024: $374 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.64 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.45 | 2021-2025 | |
| Amgen INC. | $241.29 | 2022-2025 | Evenity, Prolia, Prolia |
| Inspire Medical Systems, INC. | $230.43 | 2023-2025 | Inspire |
| Ibsa Pharma INC. | $186.71 | 2021-2024 | Tirosint, Licart, Tirosint |
| Ascendis Pharma Endocrinology INC | $158.54 | 2023-2025 | Yorvipath |
| Lilly USA, LLC | $100.82 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $100.11 | 2021-2024 | |
| Horizon Therapeutics Plc | $89.96 | 2022-2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.99 | 2021-2022 | |
| Vivus LLC | $88.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $88.14 | 2021-2022 | |
| Corcept Therapeutics | $86.61 | 2022 | |
| Amneal Pharmaceuticals LLC | $71.20 | 2021-2025 | Unithroid |
| Janssen Biotech, INC. | $67.69 | 2022-2025 | Tremfya |
| Currax Pharmaceuticals LLC | $65.79 | 2021-2023 | Nexletol, Contrave |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $62.00 | 2021-2022 | |
| Ucb, INC. | $53.07 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $49.57 | 2023-2024 | |
| Novo Nordisk INC | $35.77 | 2021 | |
| Shorla Oncology INC. | $34.09 | 2024 | |
| Irhythm Technologies, INC. | $29.25 | 2021 | |
| Mylan Institutional INC. | $20.81 | 2023 | Hulio |
| Vistapharm, INC. | $17.69 | 2021 | |
| Boston Scientific Corporation | $17.32 | 2022 | |
| Abbott Laboratories | $17.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2023 | |
| Mallinckrodt Hospital Products INC. | $14.65 | 2023 | Acthar |
| Amryt Pharma Holdings LTD | $14.53 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.23 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharla Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.